The YpsoMate autoinjector is designed for ease of use, allowing individuals with limited grip strength or vision to administer their medication safely and effortlessly. Credit: Ypsomed Group.

Global medical technology company BD has entered into a strategic partnership with Ypsomed, an injection systems manufacturer, to advance self-injection solutions specifically designed for high-viscosity biologic drugs.

The collaboration focuses on integrating BD’s Neopak XtraFlow glass prefillable syringe with Ypsomed’s YpsoMate 2.25 autoinjector platform to address the current challenges of delivering biologic drugs that have a higher viscosity (thickness) of more than 15 centipoise.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The BD Neopak XtraFlow Glass Prefillable Syringe is the latest addition to BD’s portfolio, having an 8mm needle and a thinner wall cannula that improves the subcutaneous delivery of biologics with higher viscosity profiles.

This advancement aims to push the boundaries of flow and usability, surpassing the capabilities of standard half-inch needles.

Ypsomed will expand its YpsoMate 2.25 autoinjector platform to accommodate BD’s new syringe format.

Adjustments will be made for the shorter needle, alongside tooling and assembly qualification and comprehensive technical testing to ensure device reliability.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The YpsoMate autoinjector is designed for ease of use, allowing individuals with limited grip strength or vision to administer their medication safely and effortlessly.

Ypsomed Delivery Systems chief business officer Ulrike Bauer said: “We are excited to welcome the first pharmaceutical customers to experience the benefits of the BD Neopak XtraFlow glass prefillable syringe with the YpsoMate 2.25 autoinjector.”

BD Pharmaceutical Systems worldwide president Patrick Jeukenne said: “Cross-supplier collaborations are vital in today’s pharmaceutical ecosystem.

“These partnerships can help drive innovation and ensure that systems work by design and over lifecycles, allowing our pharmaceutical partners to get life-saving therapies to patients faster.”    

In August 2024, Astria Therapeutics selected Ypsomed’s Ypsomate autoinjector as its partner for the administration of STAR-0215 for the treatment of hereditary angioedema.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact